Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.65 |
| ▸ | EBP | Q15125 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11652227 | 0.90 | SIGMAR1 (0.71) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| SCHEMBL7211284 | 0.86 | SIGMAR1 (0.52) | OPRM1OPRD1OPRK1SIGMAR1 | |
| Pentazocine SCHEMBL16107180 | 0.83 | SIGMAR1 (0.83) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| (+)-Pentazocine SCHEMBL42094 | 0.83 | SIGMAR1 (0.83) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| (+)-Pentazocine SCHEMBL3665045 | 0.83 | SIGMAR1 (0.83) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| SCHEMBL11659331 | 0.83 | OPRM1 (0.65) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| SCHEMBL11051972 | 0.82 | OPRM1 (0.61) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| SCHEMBL10031232 | 0.81 | SIGMAR1 (0.75) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| SCHEMBL11654239 | 0.81 | OPRM1 (0.61) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 | |
| Carbamic Acid SCHEMBL6120538 | 0.80 | OPRM1 (0.62) | OPRM1OPRD1OPRK1SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 963 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115737571-A | Pentazocine preparation and preparation method and application thereof | 广州市力鑫药业有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-10925864-B2 | Stable liquid injectable solution of midazolam and pentazocine | NEON LABORATORIES LIMITED (IN) | 2021-02-23 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| EP-1416920-B1 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS INC (US) | 2007-01-10 | — | — | EP | claimed |
| EP-1416920-A4 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS INC (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1416920-A2 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | Impax Pharmaceuticals Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| US-6730321-B2 | FOR TABLETS; COMPRESSION BLEND; SUSTAINED RELEASE | IMPAX PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-20030203028-A1 | Multiplex drug delivery system suitable for oral administration | IMPAX PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| US-20020164371-A1 | Press coated, pulsatile drug delivery system suitable for oral administration | IMPAX PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | claimed |
| US-6372254-B1 | Press coated, pulsatile drug delivery system suitable for oral administration | IMPAX PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | claimed |
| WO-2000018447-A2 | MULTIPLEX DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| WO-1999051209-A1 | PRESS COATED, PULSATILE DRUG DELIVERY SYSTEM SUITABLE FOR ORAL ADMINISTRATION | IMPAX PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
| US-20260144746-A1 | Protein Based Soft Chew Tablets | FERTIN PHARMA A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| US-20260144745-A1 | Sugar Free Soft Chew Tablets | FERTIN PHARMA A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | disclosed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | disclosed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144745-A1 | Sugar Free Soft Chew Tablets | SI, TREH, SLC2A3 | OPRM1 1446/4885OPRD1 1740/4885OPRK1 897/4885 |
| US-20260144746-A1 | Protein Based Soft Chew Tablets | CARHSP1, HIRA, HEATR6 | OPRM1 1937/4885OPRD1 2393/4885OPRK1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.